Company Performance Metrics
Rekha Bansal: Founder & Chief Executive Officer
NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with
large market potential and unmet medical need.
We specialize in complement-based therapies. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies target non-orphan and orphan diseases and have the potential for a better safety and efficacy profile than currently marketed drugs
